Guidance
← Отчётные звонки
01
02
03
04 05 06
Тон
A1
GILD
FY2026 Q2
Повышен
Отчётный звонок Gilead Sciences, Inc.
Вывод Buzzberg
Gilead ups full-year HIV sales growth guidance to 9-10%
Gilead reported strong Q2 2026 results driven by its HIV portfolio, Tredelvey, and Livdelzi, raising FY2026 guidance for total product sales. The company highlighted significant progress in its HIV pipeline with multiple long-acting options and a strong PrEP franchise, while also advancing its oncology portfolio through acquisitions and new approvals. Base business sales grew 10% year-over-year, with HIV sales up 12% driven by Biktarvy and the PrEP franchise.
Вывод Buzzberg Gilead ups full-year HIV sales growth guidance to 9-10% Gilead reported strong Q2 2026 results driven by its HIV portfolio, Tredelvey, and Livdelzi, raising FY2026 guidance for total product sales. The company highlighted significant progress in its HIV pipeline with multiple long-acting options and a strong PrEP franchise, while also advancing its oncology portfolio through acquisitions and new approvals. Base business sales grew 10% year-over-year, with HIV sales up 12% driven by Biktarvy and the PrEP franchise. Читать полный анализСвернуть анализ
Gilead reported strong Q2 2026 results driven by its HIV portfolio, Tredelvey, and Livdelzi, raising FY2026 guidance for total product sales. The company highlighted significant progress in its HIV pipeline with multiple long-acting options and a strong PrEP franchise, while also advancing its oncology portfolio through acquisitions and new approvals. Base business sales grew 10% year-over-year, with HIV sales up 12% driven by Biktarvy and the PrEP franchise.
- Yes2Go, a long-acting injectable PrEP, is established as the leading option with persistency rates over 70% and full-year sales target of approximately $1 billion.
- Tredelvy sales grew 26% year-over-year, driven by new approvals in first-line metastatic TNBC.
- Gilead raised its FY2026 total product sales guidance to $30.1-$30.4 billion and HIV growth guidance to 9-10%.
Выручка$7.803B+12% к/к
EPS$-6.75Факт
Свободный денежный поток$3.69B+52% к/к
Капзатраты$0.117BФакт
6 подтверждённых тезисов
Что важно сейчас
Самые значимые изменения по итогам звонка.
Demand
PrEP business reaches $4 billion annual run rate
Adoption
Yes2Go persistency at over 70% for reinjection
Показать ещё 3 тезиса
Pipeline
BicLen FDA decision expected by August 27
Pipeline
ISLEN weekly oral HIV regimen targets 2027 launch
Clinical Data
GS8824 shows 61% response rate in ovarian cancer
Отчётный период
Фактические результаты
| Показатель | Факт | Изменение |
|---|---|---|
| Выручка | $7.803B | +12% к/к |
| EPS | $-6.75 | Факт |
| Свободный денежный поток | $3.69B | +52% к/к |
| Капзатраты | $0.117B | Факт |
| Чистая прибыль | $-2.021B | Факт |
Прогнозные данные
Прогноз компании
| Показатель | Период | Диапазон | Середина | Статус |
|---|---|---|---|---|
| Выручка | FY2026 | $30.1B–$30.4B | $30.25B | Повышен |
AI, капзатраты и спрос
Оценка менеджмента
Confident
Management highlighted strong commercial execution, raised full-year HIV guidance, and pointed to multiple upcoming catalysts, reflecting a confident outlook.
все упомянутые компании ниже: 5
Компаниис момента звонка
Партнёры
PRGN
Партнёры
Dietmar Berger
The collaboration with PreGene is set to accelerate the development of Gilead's in vivo CAR-T platform with two investigator-sponsored studies, indicating a positive step for the platform.
Доказательства
“And our collaboration with PreGene enables Speed2Clinic, where we will start exploring our updated in vivo platform in two investigator-sponsored studies later this year.”
Партнёры
Dietmar Berger
The HIV PrEP market itself is growing rapidly, and Gilead's overall PrEP business is now at a $4 billion annual run rate, significantly outpacing the market. — Gilead is expanding the entire PrEP market while gaining share, potentially impacting competitors like Merck's future prevention products.
Доказательства
“highlights included oral presentations with a simultaneous publication in the New England Journal of Medicine on Gilead and Merck's once-weekly oral regimen, combining isletrovir plus lanacapivir, or ISLEN.”
Инвестиции
Инвестиции
Daniel O'Day
Gilead acquired full ownership of Arcelix's assets, indicating a positive view of its technology and a heightened focus to execute on its pipeline.
Доказательства
“The completed acquisition of Arcelex has given us full ownership of a NitoCell enabling faster, more focused execution in multiple myeloma, as well as the D-domain binder platform for future opportunities”
Инвестиции
Daniel O'Day
Gilead's acquisition of Tubulus brings an industry-leading ADC platform, signalling a positive outlook for its oncology pipeline and future growth.
Доказательства
“The acquisition of Tubulus has now closed, providing Gilead with an industry-leading ADC platform and Promising Clinical Stage ADCs.”
OROM
Инвестиции
Dietmar Berger
The acquisition of Oro medicines adds bispecific T-cell engager assets to Gilead's pipeline, indicating a diversification and strengthening of its oncology portfolio.
Доказательства
“We expanded the breadth of our innovation engine through the acquisitions of Arcelix, Tubalys, and Oromedicins, adding differentiated and potentially best-in-class cell therapy, antibody drug conjugate, and bispecific T-cell engager assets.”
Внешние сигналы
Альфа цепочки поставок · 1с момента звонка
The HIV PrEP market itself is growing rapidly, and Gilead's overall PrEP business is now at a $4 billion annual run rate, significantly outpacing the market.
Доказательства
“The U.S. PrEP market grew approximately 14% year-over-year, marking another quarter of double-digit percentage growth on an increasingly larger base of users. Gilead PrEP sales growth of over 100% has once again significantly outpaced the…”
Методология и полнота
Анализ основан только на заявлениях менеджмента. Показаны все подтверждённые упоминания компаний: 5. Фактические результаты и прогнозы разделены. Публичные доказательства ограничены восемью короткими атрибутированными цитатами. AI-анализ может быть неполным или ошибочным — проверяйте важные утверждения по первоисточнику.